{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:46:32Z","timestamp":1779212792801,"version":"3.51.4"},"reference-count":27,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Clinical Hypertension"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Sacubitril\/valsartan, simultaneously inhibits neprilysin and angiotensin II receptor, showed an effect in reducing blood pressure (BP). The authors aimed to study whether it can be used as an antihypertensive agent in patients with refractory hypertension who have already been treated. A total of 66 Chinese patients with refractory hypertension were enrolled. Patients received sacubitril\/valsartan \u00a0200 instead of angiotensin II receptor blocker or angiotensin converting enzyme inhibitor while other agents continued. If BP was uncontrolled after 4\u00a0weeks, sacubitril\/valsartan was increased to 400\u00a0mg. The BP reduction was evaluated by office BP and ambulatory BP monitoring after 8\u2010week treatment. The baseline office BP and mean arterial pressure (MAP) were 150.0\/95.0\u00a0mmHg and 113.3\u00a0mmHg. BP and MAP reduced to 130.6\/83.2\u00a0mmHg and 99.0\u00a0mmHg at week 8. Office BP and MAP reductions were 19.4\/11.8\u00a0mmHg and 14.3\u00a0mmHg at endpoint (all <jats:italic>p<\/jats:italic>\u00a0&lt;\u00a0.001). The 24\u2010h, daytime and nighttime ambulatory BP were 146.2\/89.1, 148.1\/90.3, and 137.5\/83.7\u00a0mmHg, respectively at baseline, and BP reduced to 129.6\/79.8, 130.6\/81.1, and 121.7\/75.8\u00a0mmHg, respectively at week 8. The 24\u2010h, daytime and nighttime ambulatory BP reductions were 16.6\/9.3, 17.5\/9.2, and 15.8\/7.9\u00a0mmHg, respectively at endpoint (all <jats:italic>p<\/jats:italic>\u00a0&lt;\u00a0.001). Sacubitril\/valsartan significantly reduced office and ambulatory BP in refractory hypertension patients. Our study provided new evidence for sacubitril\/valsartan in refractory hypertension.<\/jats:p>","DOI":"10.1111\/jch.14454","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T13:24:36Z","timestamp":1646659476000},"page":"449-456","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension"],"prefix":"10.1111","volume":"24","author":[{"given":"Wanjing","family":"Li","sequence":"first","affiliation":[{"name":"Department of Cardiology The First Affiliated Hospital of Dalian Medical University  Dalian Liaoning China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minghui","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Cardiology The First Affiliated Hospital of Dalian Medical University  Dalian Liaoning China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8448-8637","authenticated-orcid":false,"given":"Qin","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Cardiology The Affiliated Zhongshan Hospital of Dalian University  Dalian Liaoning China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rihui","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiology The Central Hospital of Liaoyang City Affiliated China Medical University  Liaoyang Liaoning China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaiming","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cardiology The Affiliated Central Hospital of Shenyang Medical College  Shenyang Liaoning China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Cardiology The Affiliated Shengjing Hospital of China Medical University  Dalian Liaoning China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumei","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Cardiology The Second People's Hospital of Dalian  Dalian Liaoning China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaolong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Cardiology The First Affiliated Hospital of Jinzhou Medical University  Jinzhou Liaoning China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Cardiology Dalian Locomotive Hospital  Dalian Liaoning China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4973-7236","authenticated-orcid":false,"given":"Wei","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Cardiology The First Affiliated Hospital of Dalian Medical University  Dalian Liaoning China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinong","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Cardiology The First Affiliated Hospital of Dalian Medical University  Dalian Liaoning China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,3,7]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/08037051.2019.1584975"},{"key":"e_1_2_9_3_1","first-page":"182","article-title":"2018 Chinese guidelines for prevention and treatment of hypertension \u2013 a report of the revision committee of Chinese guidelines for prevention and treatment of hypertension","volume":"16","author":"Liu LS","year":"2018","journal-title":"J\u00a0Geriatr Cardiol"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.142"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009343932"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1937-6448(08)00803-4"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.12676"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.01.033"},{"key":"e_1_2_9_9_1","first-page":"131","article-title":"Angiotensin receptor\u2010neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure","volume":"9","author":"Langenickel TH","year":"2012","journal-title":"Drug Discov Today"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61966-8"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.113.02002"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jch.12667"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2015.1"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.08484"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/08037051.2012.727253"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0828-282X(07)70733-X"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000239299.71001.77"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.109.131235"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajh.2010.217"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2007.07.020"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.107.096933"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.823112"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpx111"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-016-0972-2"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.097345"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807303390507"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.2174\/1573403X15666190625160352"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1152\/advan.00177.2016"}],"container-title":["The Journal of Clinical Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jch.14454","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jch.14454","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jch.14454","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T01:27:04Z","timestamp":1697074024000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jch.14454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,7]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1111\/jch.14454"],"URL":"https:\/\/doi.org\/10.1111\/jch.14454","archive":["Portico"],"relation":{},"ISSN":["1524-6175","1751-7176"],"issn-type":[{"value":"1524-6175","type":"print"},{"value":"1751-7176","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,7]]},"assertion":[{"value":"2021-12-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}